InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Galmed Pharmaceuticals Ltd.

GLMD Clue Score40
Israel Fiscal year ends December CIK 0001595353
Alert on the numbers Alert on insider trades

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue0.5Net income−17.0Fiscal year 2017Revenue1.1 +132.3%Operating income−12.4Net income−12.3Fiscal year 2018Revenue2.0 +87.8%Operating income−10.7Net income−9.9Fiscal year 2019Revenue0.0 −100.0%Operating income−22.4Net income−20.5Fiscal year 2020Revenue0.0Operating income−30.2Net income−28.8Fiscal year 2021Net income−32.5EPS, diluted19.80Fiscal year 2022Net income−17.9EPS, diluted127.80Fiscal year 2023Net income−6.9EPS, diluted30.00Fiscal year 2024Net income−7.5EPS, diluted8.08Fiscal year 2025Net income−10.3EPS, diluted2.39
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 0.5 1.1 2.0 0.0 0.0 n/a n/a n/a n/a n/a
Growth +132.3% +87.8% −100.0%
Operating income n/a −12.4 −10.7 −22.4 −30.2 n/a n/a n/a n/a n/a
Net income −17.0 −12.3 −9.9 −20.5 −28.8 −32.5 −17.9 −6.9 −7.5 −10.3
Growth
EPS, diluted n/a n/a n/a n/a n/a 19.80 127.80 30.00 8.08 2.39

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Net margin−3,630.2%Free cash flow margin−2,600.9%Fiscal year 2017Operating margin−1,139.5%Net margin−1,133.5%Free cash flow margin−1,113.3%Fiscal year 2018Operating margin−525.8%Net margin−483.6%Free cash flow margin−447.2%Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Fiscal year 2025
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a −1,139.5% −525.8% n/a n/a n/a n/a n/a n/a n/a
Net margin −3,630.2% −1,133.5% −483.6% n/a n/a n/a n/a n/a n/a n/a
Free cash flow margin −2,600.9% −1,113.3% −447.2% n/a n/a n/a n/a n/a n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−12.1Capital expenditure−0.0Free cash flow−12.1Fiscal year 2017Operating cash flow−12.1Capital expenditure−0.0Free cash flow−12.1Fiscal year 2018Operating cash flow−9.0Capital expenditure−0.1Free cash flow−9.1Fiscal year 2019Operating cash flow−14.9Capital expenditure−0.0Free cash flow−14.9Fiscal year 2020Operating cash flow−26.3Capital expenditure−0.0Free cash flow−26.3Fiscal year 2021Operating cash flow−32.9Capital expenditure−0.0Free cash flow−32.9Fiscal year 2022Operating cash flow−18.5Capital expenditure−0.0Free cash flow−18.5Fiscal year 2023Operating cash flow−6.1Fiscal year 2024Operating cash flow−5.9Fiscal year 2025Operating cash flow−6.3
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −12.1 −12.1 −9.0 −14.9 −26.3 −32.9 −18.5 −6.1 −5.9 −6.3
Capital expenditure −0.0 −0.0 −0.1 −0.0 −0.0 −0.0 −0.0 n/a n/a n/a
Free cash flow −12.1 −12.1 −9.1 −14.9 −26.3 −32.9 −18.5 n/a n/a n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2016Cash3.1Total debt0.8Net cash (debt)2.3Shareholders’ equity11.1Debt to equity0.07Fiscal year 2017Cash13.0Total debt0.0Net cash (debt)13.0Shareholders’ equity15.8Debt to equity0.00Fiscal year 2018Cash24.2Shareholders’ equity87.9Fiscal year 2019Cash15.9Shareholders’ equity69.9Fiscal year 2020Cash6.9Shareholders’ equity44.2Fiscal year 2021Cash2.9Shareholders’ equity30.5Fiscal year 2022Cash2.0Shareholders’ equity13.4Fiscal year 2023Cash2.9Shareholders’ equity13.9Fiscal year 2024Cash4.7Shareholders’ equity16.3Fiscal year 2025Cash4.0Shareholders’ equity15.8
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 3.1 13.0 24.2 15.9 6.9 2.9 2.0 2.9 4.7 4.0
Total debt 0.8 0.0 n/a n/a n/a n/a n/a n/a n/a n/a
Net cash (debt) 2.3 13.0 n/a n/a n/a n/a n/a n/a n/a n/a
Shareholders’ equity 11.1 15.8 87.9 69.9 44.2 30.5 13.4 13.9 16.3 15.8
Debt to equity 0.07 0.00 n/a n/a n/a n/a n/a n/a n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021† 31 Dec 2021 FY2022† 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
0.5 1.1 2.0 0.0 0.0 n/a n/a n/a n/a n/a
Growth +132.3% +87.8% −100.0%
14.3 9.7 8.3 18.2 26.1 27.2 13.0 3.6 3.0 4.9
3.1 3.8 4.4 4.2 4.1 5.7 4.7 3.9 3.3 3.6
n/a −12.4 −10.7 −22.4 −30.2 n/a n/a n/a n/a n/a
Growth
−16.8 −12.3 −9.8 −20.5 −28.8 −32.5 17.9 6.9 7.5 n/a
0.1 0.0 0.1 0.0 0.0 n/a n/a n/a n/a 0.0
−17.0 −12.3 −9.9 −20.5 −28.8 −32.5 −17.9 −6.9 −7.5 −10.3
Growth
Per share
n/a n/a n/a 0.97 1.35 19.80 127.80 30.00 8.08 2.39
n/a n/a n/a n/a n/a 19.80 127.80 30.00 8.08 2.39
Growth +545.5% −76.5% −73.1% −70.4%
n/a n/a n/a n/a n/a 1.6 0.1 0.2 0.9 4.3
n/a n/a n/a 21.1 21.3 1.6 0.1 0.2 0.9 4.3
Growth +0.8% −92.3% −91.5% +65.2% +303.3% +363.2%

† The diluted share count jumps at 2021 and 2022 and 2023 and 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 10 of 10 years on file.